Year 2016 / Volume 108 / Number 10
Original
Adalimumab versus infliximab in treating post-operative recurrence of Crohn’s disease: a national cohort study

642-647

DOI: 10.17235/reed.2016.4483/2016

Carmen-Monica Preda, Larisa Elena Fulger, Lucian Negreanu, Mircea Manuc, Irina Sandra, Mircea-Mihai Diculescu,

Abstract
Aim: Perform a comparison between adalimumab (ADA) and infliximab (IFX) in treating post-operative recurrence of Crohn's disease (a comparative analysis of efficacy and safety). Methods: From the 267 patients treated with Adalimumab or Infliximab between January 2005 and June 2014 in Romania, 44 received anti- TNF (tumor necrosis factor) therapy for prevention of post-operative recurrence. A comparison between patients treated with IFX and ADA was made with the Chi- square and t- student test, with the aid of the statistical program Mini Tab 17. Results: Twenty-one patients received IFX and 23 ADA. This included 49% males (22/44), with a mean age of 41 years, mean disease duration of 6 years, and 84.1% had previously received azathioprine. The IFX group is comparable with the ADA group regarding most of the parameters, except for therapy duration. Mean duration of therapy was 33 months. The rate of complete response was comparable between the two groups: 67% in the IFX group vs. 78.3% in the ADA group, the same as the rate of re-resection, 19.1% vs. 4.4% and the rate of endoscopic recurrence, 29 vs. 33% at 12 months. Risk factors for postoperative recurrence (POR) (male sex, younger age, ileocolonic location, stricturing or penetrating behaviour) were studied, only ileocolonic location was found to be associated with Crohn's disease recurrence in patients treated with ADA. Conclusions: Overall infliximab and aalimumab are equally efficient in patients with resected Crohn's disease (CD) with a complete response of 72.7%, a rate of re-resection of 11.4 % and a rate of endoscopic recurrence of 35%. Ileocolonic location might be a predictive factor for loss of response to adalimumab in resected Crohn's disease patients.
Share Button
New comment
Comments
No comments for this article
References
1. Van Assche G , Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis 201; 4: 7–27 [PMID: 21122488 DOI:10.1016/j.crohns.2009.12.003].
2. Spinelli A, Sachhi M, Fiorino G, Danese S, Montorsi M. Risk of postoperative recurrence and postoperative management of Crohn’s disease. World J Gastroenterol 2011; 17(27): 3213-3219 [PMID: 21912470 DOI: 10.3748/wjg.v17.i27.3213]
3. Cho SM, Cho SW, Regueiro M. Postoperative management of crohn disease. Gastroenterol Clin North Am 2009; 38: 753-762 [PMID: 19913212 DOI: 10.1016/j.gtc.2009.07.008]
4. Van Loo E S, Dijkstra G, Ploeg R J, Nieuwenhuijs V B. Prevention of postoperative recurrence of Crohn's disease. Journal of Crohn's and Colitis (2012) 6, 637–646 [PMID: 24189041 DOI:10.1097/01.MIB.0000435758.97952.a8]
5. Van Assche G, Dignass A, Reinisch A, Janneke van der Woude C, Sturm A, et al. for the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. Journal of Crohn's and Colitis (2010) 4, 63–101 [PMID: 2112249 DOI:10.1016/j.crohns.2009.09.009]
6. Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005; 11(26):3971–9. [PMID: 15996018]
7. Regueiro M, Schraut W, Baidoo L, Kip K, Sepulveda A, Pesci M, et al. Infliximab Prevents Crohn’s Disease Recurrence After Ileal Resection. Gastroenterology 2009;136:441–450 [PMID: 19109962 DOI:10.1053/j.gastro.2008.10.051]
8. Terdiman JP. Prevention of postoperative recurrence in Crohn’s disease. Clin Gastroenterol Hepatol 2008;6:616–620. [PMID: 17967564]
9. Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004;187:219–25. [PMID: 14769308]
10. Sachar DB, Lemmer E, Ibrahim C, Edden Y, Ullman T, Ciardulo J, et al. Recurrence patterns after first resection for stricturing or penetrating Crohn's disease. Inflamm Bowel Dis 2009;15(7):1071–5. [PMID: 19229992 DOI: 10.1002/ibd.20872]
11. Hofer B, Bottger T, Hernandez-Richter T, Seifert JK, Junginger T. The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn's disease. Hepatogastroenterology 2001;48:152–5. [PMID: 11268954]
12. Onali S, Petruzziello C, Calabrese E, Condino G, Zorzi F, Sica GS, et al. Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic. J Gastrointest Surg 2009;13:246–52 [PMID: 18949525 DOI: 10.1007/s11605-008-0726-1]
13. Vaughn B P, Moss A. Prevention of post-operative recurrence of Crohn’s disease. World J Gastroenterol 2014; 20(5): 1147-1154 [PMID: 24574791 DOI: 10.3748/wjg.v20.i5.1147]
14. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 2004; 127: 730-740 [PMID: 15362028]
15. Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128(4): 856-861 [PMID: 15825069]
16. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009; 136:441–450 [PMID: 19109962 DOI: 10.1053/j.gastro.2008.10.051]
17. Aguas M, Bastida G, Cerrillo E, Beltrán B, Iborra M, Sánchez-Montes C, et al Adalimumab in prevention of postoperative recurrence of Crohn’s disease in high-risk patients. World J Gastroenterol 2012; 18:4391–4398 [PMID: 22969204 DOI: 10.3748/wjg.v18.i32.4391]
18. Armuzzi A, Felice C, Papa A, Marzo M, Pugliese D, Andrisani G, et al Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn’s disease: an open-label pilot study. J Crohns Colitis 2013: 7:e623–e629 [PMID: 23810678 DOI: 10.1016/j.crohns.2013.04.020]
19. Tursi A, Elisei W, Picchio M, Zampaletta C, Pelecca G, Faggiani R, et al. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn’s disease: an open-label, pilot study. Tech Coloproctol. 2014;18(11):1041-6 [PMID:24915941 DOI: 10.1007/s10151-014-1177-1]
20. Papamichael K , Archavlis E, Lariou C, Mantzaris G. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: A prospective, two-year, single center, pilot study. J Crohns Colitis 2012; 9: 924-931 [PMID: 22424843 DOI:10.1016/j.crohns.2012.02.012]
21. Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, et al Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolonic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 2012; 18: 1617–1623 [PMID:22081474 DOI: 10.1002/ibd.21928]
Related articles

Letter

Isolated Jejunal Crohn's Disease: a challenging diagnosis

DOI: 10.17235/reed.2022.9423/2022

Letter

Comb sign in Crohn’s disease

DOI: 10.17235/reed.2022.9132/2022

Letter

Ectopic ACTH syndrome in a patient with Crohn’s disease

DOI: 10.17235/reed.2022.8825/2022

Letter

Pulmonary nodules in a patient with Crohn’s disease

DOI: 10.17235/reed.2022.8499/2021

Letter

Adenocarcinoma of the small intestine in Crohn's disease

DOI: 10.17235/reed.2021.8050/2021

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Citation tools
Preda C, Fulger L, Negreanu L, Manuc M, Sandra I, Diculescu M, et all. Adalimumab versus infliximab in treating post-operative recurrence of Crohn’s disease: a national cohort study. 4483/2016


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 3547 visits.
This article has been downloaded 107 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 02/06/2016

Accepted: 16/08/2016

Online First: 21/09/2016

Published: 30/09/2016

Article revision time: 67 days

Article Online First time: 111 days

Article editing time: 120 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology